# Assessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAs: Draft Guidance for Industry - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/assessing-the-irritation-and-sensitization-potential-of-transdermal-and-topical-delivery-systems-for-andas-draft-guidance-for-industry/1472ed4f-fea1-4017-b0d7-d7fcd5e86e6d

> FDA guidance document: Assessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAs: Draft Guidance for Industry. Issue date: April 13, 2023. Get complete insights and analysis.

---

## Details

- Title: Assessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAs: Draft Guidance for Industry
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2023-04-13
- Comment Close Date: 2023-06-12
- Last Changed: 2023-04-14
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2018-D-3546">FDA-2018-D-3546</a>

## Related Documents

- [Quality Considerations for Topical Ophthalmic Drug Products](https://www.globalkeysolutions.net/guidances/guidance-document/quality-considerations-for-topical-ophthalmic-drug-products/19494a43-f26e-42c9-b1ad-99a1126b3d42)
- [Topical Dermatologic Corticosteroids:  In Vivo Bioequivalence](https://www.globalkeysolutions.net/guidances/guidance-document/topical-dermatologic-corticosteroids-in-vivo-bioequivalence/7cf691b8-82e3-41a4-a550-b4285ce9a9bf)
- [Assessing Adhesion With Transdermal and Topical Delivery Systems for ANDAs Draft Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/assessing-adhesion-with-transdermal-and-topical-delivery-systems-for-andas-draft-guidance-for-industry/2987a560-17ed-4e62-b674-1c17e17f5298)